17th May 2007 07:01
Oxford Biomedica PLC17 May 2007 For Immediate Release 17 MAY 2007 OXFORD BIOMEDICA ANNOUNCES THAT PHASE II RESULTS WITH HI-8(R) MEL IN MELANOMA WILL BE PRESENTED AT AMERICAN ASSOCIATION OF IMMUNOLOGISTS MEETING Oxford, UK: 17 May 2007: Oxford BioMedica (LSE: OXB), the leading gene therapycompany, today announces that scientists from its wholly owned subsidiary, OxxonTherapeutics, and its clinical collaborators will present results from a PhaseII trial of Hi-8 MEL in melanoma at the American Association of Immunologists(AAI) Annual Meeting, to be held on 18-22 May in Miami, Florida. The abstracthas been selected for both an oral and a poster presentation. The presentation will include updated data from the completed Phase II trial ofHi-8 MEL in 41 patients with Stage III/IV melanoma, which was conducted atmultiple sites in the UK and Germany. The trial was designed to evaluate theimmune and clinical responses elicited by the prime-boost immunotherapeuticvaccine, Hi-8 MEL. The product consists of a recombinant DNA vaccine andmodified vaccinia virus Ankara (MVA), both of which have been engineered tocontain DNA that encodes a string of seven cytotoxic T-cell epitopes from fivemelanoma antigens. The presentation will include further follow-up of a patient that exhibited botha sustained partial clinical response (tumour shrinkage) and also a strongantigen-specific immune response following treatment. In addition, thepresentation will highlight previously reported data on immunogenicity andclinical benefit. The product was highly immunogenic with 91% of patients thatreceived the optimal dose showing an antigen-specific immune response. In termsof clinical benefit, eight patients (20%) showed disease control, including thepatient with a partial response and an additional seven patients with periods ofstable disease. The median survival for immune responders was 100 weeks versus37 weeks for non-responders (pRelated Shares:
Oxford Biomedica